| HOME >> BIOLOGY >> TECHNOLOGY |
TARRYTOWN, N.Y., Oct. 15 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Dr. John Drewe, Senior Director of Lead Discovery, will be presenting at the IBC conference on Assays and Cellular Targets at the Hotel Del Coronado in San Diego, CA on October 17, 2007. Dr. Drewe will describe the advances into pre-clinical testing of drug discovery efforts targeting the Myc oncogene pathway utilizing EpiCept's Anti-cancer Screening Apoptosis Platform (ASAP).
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
The presentation will focus on the rapid identification and optimization of lead product candidates related to the Myc oncogene pathway which utilized the cell- and caspase-based apoptosis induction assay for both discovery and successive structure-activity relationship studies. Oncogenes such as Myc play a key role in the regulation of processes in both normal and cancer cells. Deregulation of Myc expression is intimately linked to development of several cancers and has been a difficult target for drug discovery. EpiCept's ASAP technology provides a means for identification of compounds targeting the Myc pathway that lead to apoptosis, or programmed cell death. Optimization by medicinal chemistry has led to the identification of a compound that is highly efficacious in vivo in Myc deregulated tumor models. The ASAP technology has also identified two anticancer drug candidates currently in clinical development, EPC2407 in Phase I and Azixa(TM)* in Phase II trials.
About EpiCept's ASAP Technology
Cancerous cells often exhibit unchecked growth caused by the disabling
or absence of the natural process of programmed cell death, which is called
apoptosis. Apoptosis is normally triggered to destroy a cell from within
when it outlives its purpose or it is seriously damaged. One of the most
promi
'/>"/>
| SOURCE EpiCept Corporation Copyright©2007 PR Newswire. All rights reserved |